Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 2, 2013, Pages 315-322

  Chen, Cui ^a   Wang, Fenghua ^a   Wang, Zhiqiang ^a   Li, Cong ^a   Luo, Huiyan ^a   Liang, Ying ^a   An, Xin ^a   Shao, Jianyong ^a   Li, Yuhong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cisplatin based chemotherapy; DNA repair; Metastatic recurrent NPC; Polymorphisms

Indexed keywords

CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GENOMIC DNA; PACLITAXEL;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; DNA ADDUCT; DNA EXTRACTION; DNA REPAIR; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; MOUSE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENT CANCER; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGING; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SAMPLE SIZE; SEX CHARACTERISTICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 84880917856     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2196-8     Document Type: Article

References (30)

1. Chang ET, Adami HO (2006) The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15(10):1765-1777 (Pubitemid 44664247)
2. Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H, Boussen H, Errihani H (2011) Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 128(2):79-85
3. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM (2003) DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66(2):225-237 (Pubitemid 36776396)
4. Bernig T, Chanock SJ (2006) Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn 6(3):319-331 (Pubitemid 44174338)
5. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21(4):551-555 (Pubitemid 30214005)
6. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, Mark EJ, Wain JC, Christiani DC, Kelsey KT (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21(5):965-971 (Pubitemid 30265141)
7. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA (2008) Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 26(21):3598-3606
8. Khrunin AV, Moisseev A, Gorbunova V, Limborska S (2010) Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 10(1):54-61
9. Steffensen KD, Waldstrom M, Jeppesen U, Brandslund I, Jakobsen A (2008) Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 18(4):702-710 (Pubitemid 352020157)
10. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F (2005) ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11(17):6212-6217 (Pubitemid 41262950)
11. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61(24):8654-8658 (Pubitemid 34013872)
12. Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Cespedes M (2006) DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24(26):4333-4339 (Pubitemid 46630792)
13. Park SY, Hong YC, Kim JH, Kwak SM, Cho JH, Lee HL, Ryu JS (2006) Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol 23(4):489-498
14. Ren S, Zhou S, Wu F, Zhang L, Li X, Zhang J, Xu J, Lv M, Zhang J, Zhou C (2012) Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer 75(1):102-109
15. Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, Wheatley-Price P, Waldron J, Goldstein D, Meyer F, Bairati I, Liu G (2008) Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev 17(3):490-499 (Pubitemid 351469197)
16. Cheng XD, Lu WG, Ye F, Wan XY, Xie X (2009) The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Exp Clin Cancer Res 28:91
17. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22(13):2594-2601 (Pubitemid 41103746)
18. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ (2012) Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol 7(6):973-981
19. Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24(5):331-344 (Pubitemid 28537769)
20. Reed E (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11(17):6100-6102 (Pubitemid 41262934)
21. Enzlin JH, Scharer OD (2002) The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly conserved nuclease motif. EMBO J 21(8):2045-2053 (Pubitemid 34437202)
22. Lee HW, Hwang YH, Han JH, Choi JH, Kang SY, Jeong SH, Ann MS, Oh YT, Kim JH, Kim CH, Sheen SS (2010) High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncol 46(3):209-213
23. Huang PY, Li Y, Mai HQ, Luo RZ, Cai YC, Zhang L (2012) Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncol 48(10):964-968
24. Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, Kometani T, Shoji F, Yoshino I, Maehara Y (2010) Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67(1):101-107
25. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16(3):555-560
26. Park D, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz H-J (2002) ERCC1 polymorphism is associated with differential ERCC1 gene expression. American Association for Cancer Research, San Francisco, CA
27. Woelfelschneider A, Popanda O, Lilla C, Linseisen J, Mayer C, Celebi O, Debus J, Bartsch H, Chang-Claude J, Schmezer P (2008) A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis 29(9):1758-1764
28. Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, Heist RS, Rosell R, Booton R, Wei Q (2011) No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 72(3):370-377
29. Tay MH, Ong YK, Foo KF (2001) The role of salvage chemotherapy in metastatic nasopharyngeal carcinoma (NPC). Proc Am Soc Clin Oncol 20 (abstract2547)
30. Ma BB, Hui EP, Wong SC, Tung SY, Yuen KK, King A, Chan SL, Leung SF, Kam MK, Yu BK, Zee B, Chan AT (2009) Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma - correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol 20(11):1854-1859